Astellas announced that China NMPA approved XTANDI for the treatment of prostate cancer
The FINANCIAL -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the China National ...
ADVERTISEMENT
Tag: PROSPER trial
ADVERTISEMENT
Popular Last 24h
-
Quantum Computing, Inc. Announces Private Placement of Common Stock for Proceeds of $100 Million
-
Crews battle fire at Cleveland Metroparks Zoo’s Rainforest exhibit
-
Rodrigo Bentancur needed stretchering off after a sickening head injury
-
The UK Government has announced a full asset freeze against Blood and Honour.
-
Justice Department Files Voting Rights Suit Against City of Hazleton, Pennsylvania
-
SAG Awards 2025 Nominations
-
Why Enterprises Need AI Query Engines to Fuel Agentic AI
LATEST POSTS
LATESTINTERVIEWS
ADVERTISEMENT
